Litcius/Paper detail

First Report of Multidrug-Resistant Carbapenemase-Producing Bacteria Coharboring <i>mcr-9</i> Associated with Respiratory Disease Complex in Pets: Potential of Animal-Human Transmission

Hazim O. Khalifa, Atef Oreiby, Amer Ali Abd El‐Hafeez, Takashi Okanda, Anwaral Haque, Kazi Selim Anwar, Masaki Tanaka, Keisuke Miyako, Shoji Tsuji, Yasuyuki Kato, Tetsuya Matsumoto

2020Antimicrobial Agents and Chemotherapy36 citationsDOIOpen Access PDF

Abstract

Carbapenem and colistin antibiotics have been classified as critically important antimicrobial agents and are reserved primarily for the treatment of severe infection caused by multidrug-resistant bacteria (1–3). Colistin was frequently used for decades to treat and prevent infectious diseases in animals (4, 5). In contrast, carbapenem was prohibited for use in veterinary medicine in the United States based on the Animal Medicinal Drug Use Clarification Act of 1994, as well as similar rules in other countries, including members of the European Union (EU) and Australia (1). This is the first report to confirm the coproduction of MCR-9 and VIM-4 from animals, the first identification of OXA-244 from animals, and the first report to confirm their potential animal-human transmission.

Topics & Concepts

ColistinAntibioticsInfectious disease (medical specialty)Multiple drug resistanceAntimicrobialEuropean unionBovine respiratory diseaseMedicineHuman diseaseCarbapenemBiologyIntensive care medicineDiseaseMicrobiologyInternal medicineBusinessEconomic policyAntibiotic Resistance in BacteriaPharmaceutical and Antibiotic Environmental ImpactsSalmonella and Campylobacter epidemiology